{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:11Z","timestamp":1792068851879,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118816","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:17:12Z","timestamp":1790896632000},"page":"118816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pyridine-core scaffolds suppress A549 lung cancer cell progression: Evaluation of the antiproliferative activity, apoptosis, ROS generation, clonogenic suppression, and EGFR expression"],"prefix":"10.1016","volume":"143","author":[{"given":"K.B. Sachin","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.D.","family":"Satyanarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vedavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Vishwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Kumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118816_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bmc.2026.118816_bb0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/D4MD00617H","article-title":"Novel benzenesulfonamides containing a dual triazole moiety with selective carbonic anhydrase inhibition and anticancer activity","volume":"16","author":"Buza","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216623","article-title":"Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer","volume":"584","author":"Damiescu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bmc.2026.118816_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1660125","article-title":"Global, regional, and national burden of 34 cancer groups across 204 countries and territories, 1990\u20132021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"15","author":"Zhu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bmc.2026.118816_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-015-0049-8","article-title":"Cancer classification in the genomic era: five contemporary problems","volume":"9","author":"Song","year":"2015","journal-title":"Hum Genomics"},{"key":"10.1016\/j.bmc.2026.118816_bb0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/clinchem\/hvad202","article-title":"Epidemiology of cancer","volume":"70","author":"Schwartz","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061794","article-title":"Genesis and mechanism of some cancer types and an overview on the role of diet and nutrition in cancer prevention","volume":"27","author":"Kamal","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118816_bb0040","first-page":"22","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bmc.2026.118816_bb0045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acs.jmedchem.3c01093","article-title":"Discovery of novel aminobutanoic acid-based ASCT2 inhibitors for the treatment of non-small-cell lung cancer","volume":"67","author":"Qin","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review","volume":"4","author":"Zhao","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bmc.2026.118816_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bmc.2026.118816_bb0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/jmg.2006.046102","article-title":"Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer","volume":"44","author":"Zhang","year":"2007","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bmc.2026.118816_bb0065","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3892\/or.2013.2298","article-title":"Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells","volume":"29","author":"Li","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bmc.2026.118816_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bmc.2026.118816_bb0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1248\/cpb.c14-00016","article-title":"Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents","volume":"62","author":"Yassen","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bmc.2026.118816_bb0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rmed.2011.10.015","article-title":"Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies","volume":"106","author":"Stella","year":"2012","journal-title":"Respir. Med."},{"key":"10.1016\/j.bmc.2026.118816_bb0085","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1016\/j.bmcl.2012.07.079","article-title":"Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors","volume":"22","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2026.118816_bb0090","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.1021\/acs.jpcb.4c06246","article-title":"Furopyridine derivatives as potent inhibitors of the wild type, L858R\/T790M, and L858R\/T790M\/C797S EGFR","volume":"128","author":"Todsaporn","year":"2024","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bmc.2026.118816_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116727","article-title":"Design and synthesis of novel thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance mutations in non-small cell lung cancer","volume":"276","author":"Borude","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0100","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.bmc.2026.118816_bb0105","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3892\/ol.2015.3277","article-title":"Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma","volume":"10","author":"Lin","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bmc.2026.118816_bb0110","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajoms.2015.08.002","article-title":"Immunohistochemical and genetic evaluations of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma","volume":"28","author":"Abe","year":"2016","journal-title":"Oral Maxillofac Surg Med Pathol"},{"key":"10.1016\/j.bmc.2026.118816_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bmc.2026.118816_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127440","article-title":"Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: a review","volume":"253","author":"Wang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bmc.2026.118816_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117268","article-title":"Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy (2006 -present)","volume":"286","author":"An","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bmc.2026.118816_bb0130","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.bmc.2017.03.039","article-title":"Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle","volume":"25","author":"Patel","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14740338.2016.1192605","article-title":"Safety of gefitinib in non-small cell lung cancer treatment","volume":"15","author":"Hsiue","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bmc.2026.118816_bb0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.bmc.2026.118816_bb0145","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.bmc.2026.118816_bb0150","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bmc.2026.118816_bb0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.lungcan.2013.08.023","article-title":"Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors","volume":"82","author":"Sun","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmc.2026.118816_bb0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2026.118816_bb0165","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1517\/13543780903305428","article-title":"Neratinib: an oral, irreversible dual EGFR\/HER2 inhibitor for breast and non-small cell lung cancer","volume":"18","author":"Bose","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bmc.2026.118816_bb0170","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S1470-2045(12)70124-9","article-title":"A new generation of EGFR tyrosine-kinase inhibitors in NSCLC","volume":"13","author":"Hirsch","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bmc.2026.118816_bb0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cllc.2024.12.003","article-title":"Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial","volume":"26","author":"Goldman","year":"2025","journal-title":"Clin Lung Cancer."},{"key":"10.1016\/j.bmc.2026.118816_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2026.118816_bb0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"For the FLAURA Investigators Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bmc.2026.118816_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmc.2026.118816_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.132730","article-title":"Synthesis, anti-cancer activity and molecular docking studies of new nicotinamide containing EP4 antagonists","volume":"1260","author":"Ali","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bmc.2026.118816_bb0200","doi-asserted-by":"crossref","DOI":"10.1007\/s44442-025-00004-2","article-title":"EGFR tyrosine kinase inhibitor: design, synthesis, characterization, biological evaluation, and molecular docking of novel 1,3,4-oxadiazole, thio-methyl, and 1,2,3-triazole hybrids","volume":"29","author":"Alshamari","year":"2025","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.bmc.2026.118816_bb0205","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","article-title":"An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u22122023)","volume":"67","author":"Marshall","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0210","doi-asserted-by":"crossref","first-page":"15385","DOI":"10.1039\/D2RA01571D","article-title":"Pyridine: the scaffolds with significant clinical diversity","volume":"12","author":"De","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bmc.2026.118816_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-53228-4","article-title":"Novel pyridine bearing pentose moiety-based anticancer agents: design, synthesis, radioiodination and bioassessments","volume":"14","author":"Mehany","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bmc.2026.118816_bb0220","doi-asserted-by":"crossref","first-page":"12184","DOI":"10.1039\/D3RA00416C","article-title":"Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies","volume":"13","author":"Al-Muntaser","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.bmc.2026.118816_bb0225","series-title":"Pyridine and Its Derivatives","first-page":"375","article-title":"Pyridine ring as an important scaffold in anticancer drugs","author":"Elagamy","year":"2023"},{"key":"10.1016\/j.bmc.2026.118816_bb0230","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1039\/D5MD00861A","article-title":"Novel pyrido[2,3-b][1,4]oxazine-based EGFR-TK inhibitors: rational design and synthesis of potent and selective agents targeting resistance mutations in non-small cell lung cancer","volume":"17","author":"Yadav","year":"2026","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137906","article-title":"Synthesis of novel cyanopyridine compounds as potential EGFR inhibitors targeting A549 and PC3 cancer cell lines: in vitro, in vivo and ADME pharmacokinetics studies","volume":"1306","author":"Eltamany","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bmc.2026.118816_bb0240","doi-asserted-by":"crossref","first-page":"24830","DOI":"10.1021\/acs.jmedchem.5c02894","article-title":"Fragment-to-lead medicinal chemistry publications in 2024: a tenth annual perspective","volume":"68","author":"Twigg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0245","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","article-title":"Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0250","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bmcl.2018.12.065","article-title":"Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes","volume":"29","author":"He","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2026.118816_bb0255","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0260","article-title":"Discovery of novel thiophene[2,3-d]pyrimidine\u2013thiazole derivative as promising MNK inhibitor to treat breast cancer","volume":"1321","author":"Zhu","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bmc.2026.118816_bb0395","article-title":"Discovery of novel hydroxyamidine-based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors","volume":"245","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0265","article-title":"Design, synthesis and anticancer screening of cu-catalyzed SnAr substituted pyridine bridged ring systems","volume":"1277","author":"B N N, Rahman A, Jain RSK, Manjunath KS, Kumaraswamy HM, Mahadevan KM, Satyanarayan ND.","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bmc.2026.118816_bb0270","article-title":"Palladium-catalysed C\u2013C bond forming 4-cyanophenyl-nicotinamide conjugates; anti-pancreatic cancer screening on Capan-1 cell line","volume":"8","author":"Rahman","year":"2023","journal-title":"ChemSelect"},{"key":"10.1016\/j.bmc.2026.118816_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29235549","article-title":"Exploring 4,7-disubstituted pyrimido[4,5-d]pyrimidines as antiviral and anticancer agents","volume":"29","author":"Georgiou","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118816_bb0280","doi-asserted-by":"crossref","unstructured":"Benedetto Tiz D. FDA-approved drugs containing amide functionality in the last five years (2021\u20132025): pharmaceutical use, trends and synthetic approaches. Medicines (Basel, Switzerland);13:22. doi:https:\/\/doi.org\/10.3390\/medicines13030022.","DOI":"10.3390\/medicines13030022"},{"key":"10.1016\/j.bmc.2026.118816_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.matpr.2023.08.119","article-title":"Green synthesis, DFT and molecular docking studies of 4-amino indane derived Schiff bases","author":"Kasula","year":"2023","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.bmc.2026.118816_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25153493","article-title":"Impact of cross-coupling reactions in drug discovery and development","volume":"25","author":"Buskes","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118816_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107108","article-title":"Recent advances in biocatalytic C\u2013N bond-forming reactions","volume":"144","author":"Yin","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23102615","article-title":"Amide bond activation of biological molecules","volume":"23","author":"Mahesh","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118816_bb0305","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1515\/pac-2023-1104","article-title":"The amide group and its preparation methods by acid-amine coupling reactions: an overview","volume":"96","author":"Agudo-Alvarez","year":"2024","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.144031","article-title":"Pyridine and pyrimidine derivatives, potent pharmacophores with various biological activities and significant therapeutic properties: recent advances","volume":"1350","author":"Benkirane","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bmc.2026.118816_bb0315","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1021\/acschemneuro.5c00204","article-title":"Stereoisomers of chiral methyl-substituted symmetric and asymmetric aryl piperazinium compounds exhibit distinct selectivity for \u03b19 and \u03b17 nicotinic acetylcholine receptors","volume":"16","author":"Andleeb","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bmc.2026.118816_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106968","article-title":"Tetrahydrobenzothiophene derivatives ameliorate Mia PaCa-2 cell progression and induce apoptosis via inhibiting EGFR2 tyrosine kinase signal","volume":"143","author":"Rahman","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bmc.2026.118816_bb0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/cancers11040455","article-title":"CX chemokine receptor 7 contributes to survival of KRAS-mutant non-small cell lung cancer upon loss of epidermal growth factor receptor","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.bmc.2026.118816_bb0330","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","article-title":"Differential effects of gefitinib and cetuximab on non\u2013small-cell lung cancers bearing epidermal growth factor receptor mutations","volume":"97","author":"Mukohara","year":"2005","journal-title":"JNCI"},{"key":"10.1016\/j.bmc.2026.118816_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108861","article-title":"Chalcone-inspired indole, carbazole, and phenothiazine hybrids as potent aldose reductase inhibitors with selective anticancer potential: rational design, synthesis, and multi-level characterization","volume":"164","author":"G\u00fcle\u00e7","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0340","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s43440-020-00171-6","article-title":"Thymol induces mitochondrial pathway-mediated apoptosis via ROS generation, macromolecular damage and SOD diminution in A549 cells","volume":"73","author":"Balan","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bmc.2026.118816_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103798","article-title":"2-Anilinopyrimidine derivatives: design, synthesis, in vitro antiproliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study","volume":"99","author":"AboulWafa","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010362","article-title":"Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH","volume":"18","author":"Swiatnicki","year":"2022","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bmc.2026.118816_bb0355","doi-asserted-by":"crossref","first-page":"45935","DOI":"10.1074\/jbc.M406486200","article-title":"Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase","volume":"279","author":"Ambasta","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0360","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-023-36978-z","article-title":"Amide-to-ester substitution as a stable alternative to N-methylation for increasing membrane permeability in cyclic peptides","volume":"14","author":"Hosono","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bmc.2026.118816_bb0365","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2008.05.017","article-title":"Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line","volume":"63","author":"Rho","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmc.2026.118816_bb0370","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1039\/D2SC06860E","article-title":"Discovery of a photoactivatable dimerized STING agonist based on the benzo[b]selenophene scaffold","volume":"14","author":"Liu","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bmc.2026.118816_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108689","article-title":"Fluorenyl-phthalimide hybrids as potent aldose reductase inhibitors with selective anticancer activity: rational design, synthesis, and molecular insights","volume":"163","author":"Gundogdu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2022.100880","article-title":"Molecular modeling in drug discovery","volume":"29","author":"Adelusi","year":"2022","journal-title":"Inform Med Unlocked"},{"key":"10.1016\/j.bmc.2026.118816_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108788","article-title":"N-substituted phthalimide\u2013carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling","volume":"163","author":"Zognjani","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118816_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900108","article-title":"Pharmacophore modeling, 3D-QSAR, synthesis, and anti-lung cancer evaluation of novel thieno[2,3-d][1,2,3]triazines targeting EGFR","volume":"353","author":"Elrayess","year":"2020","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmc.2026.118816_bb0400","first-page":"271","article-title":"MTT assay protocol","author":"Arunachalam","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bmc.2026.118816_bb0405","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/tox.23377","article-title":"A natural derivative from ethnomedicinal mushroom potentiates apoptosis, autophagy and attenuates cell migration, via fine tuning the Akt signaling in human lung adenocarcinoma cells (A549)","volume":"37","author":"Nandi","year":"2022","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.bmc.2026.118816_bb0410","article-title":"Induction of intrinsic apoptotic signaling pathway in A549 lung cancer cells using silver nanoparticles from Gossypium hirsutum and evaluation of in vivo toxicity","volume":"23","author":"Kanipandian","year":"2019","journal-title":"Biotechnol Rep"},{"key":"10.1016\/j.bmc.2026.118816_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109347","article-title":"Comprehensive analysis and outcomes of hybridization of physiologically active heterocycles targeting epidermal growth factor receptor (EGFR)","volume":"184","author":"Kaur","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bmc.2026.118816_bb0420","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/s41598-019-38575-x","article-title":"Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expressing bladder cancer using combination photoimmunotherapy","volume":"9","author":"Siddiqui","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bmc.2026.118816_bb0425","article-title":"Exploration of new 5-chloro-7-iodo quinoline core analogues as anti-pancreatic cancer hits targeting MIA PaCa-2: EGFR inhibition","volume":"1360","author":"Vedavi","year":"2026","journal-title":"J. Mol. Struct."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:35:24Z","timestamp":1792067724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":85,"alternative-id":["S0968089626002725"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118816","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyridine-core scaffolds suppress A549 lung cancer cell progression: Evaluation of the antiproliferative activity, apoptosis, ROS generation, clonogenic suppression, and EGFR expression","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118816"}}